Answers are grounded in this paper and cite their sources.
Background: Development of immuno-oncology therapies (IO) has transformed the treatment of various cancers. However, access to IO is extremely limited in low- and lower-middle-income countries (LLMICs), despite evidence of better clinical effectiveness than traditional cancer treatment modalities.Objective: This study examines the minimum requirements for introducing IO into health systems in LLMICs.Method: Using a theme-based approach, a structured literature review was deployed to examine the accessibility of cancer medicines in LLMICs. Key informant interviews were conducted to validate the findings.Results: The study found that the existence of a basic health system infrastructure necessary for IO products to be used effectively was much lower in LLMICs. The availability of companion biomarker tests (PD-L1 and EGFR) in LLMICs is extremely limited. Additional safeguards such as cushioning packaging and extensive thermal insulation for shipping IO products are not readily available. Specialized commercial arrangements are usually required for IO market access, which are difficult to establish in LLMICs. To address these infrastructural gaps, scalable solutions such as the ATOM initiative and City Cancer Challenge are required.Conclusion: IO have particular infrastructure requirements, and many still need to be developed in LLMICs. This realization should not be seen as a barrier, but as a catalyst for multi-stakeholder collaboration and partnerships in developing sustainable solutions to enable access to IO in LLMICs.
No takes yet. Share an insight, caveat, or question.
Adeyemo et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: